![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Awards Orphan Drug Status to Immunocore for Uveal Melanoma Candidate
FDA Awards Orphan Drug Status to Immunocore for Uveal Melanoma Candidate
January 29, 2016
U.K.-based Immunocore has nabbed orphan drug status from the FDA for IMCgp100, a candidate for the treatment of uveal melanoma.
There are currently no effective treatments on the market for the disease, which affects the eye and makes up roughly 3 percent of all melanomas. The treatment is currently in Phase 2a clinical trials.
Upcoming Events
-
21Oct